Effects of human cathelicidin antimicrobial peptide LL‐37 on lipopolysaccharide‐induced nitric oxide release from rat aorta in vitro

Background: Lipopolysaccharides (LPS), released by Gram‐negative bacteria, cause vascular expression of inducible nitric oxide synthase (iNOS) leading to nitric oxide (NO) production and septic shock. Human cathelicidin antimicrobial peptide (LL‐37) can bind and neutralize LPS. We wanted to study whether LL‐37 affects LPS or interleukin‐1β (IL‐1β)‐induced production, release and function of NO in intact rat aorta rings and cultured rat aorta smooth muscle cells.

[1]  C. Ciornei,et al.  Bactericidal/permeability‐increasing protein inhibits endotoxin‐induced vascular nitric oxide synthesis , 2002, Acta anaesthesiologica Scandinavica.

[2]  E. Fleck,et al.  TNFα Inhibits Insulin's Antiapoptotic Signaling in Vascular Smooth Muscle Cells , 2001 .

[3]  I. Nagaoka,et al.  Cathelicidin Family of Antibacterial Peptides CAP18 and CAP11 Inhibit the Expression of TNF-α by Blocking the Binding of LPS to CD14+ Cells1 , 2001, The Journal of Immunology.

[4]  D. Landry,et al.  The pathogenesis of vasodilatory shock. , 2001, The New England journal of medicine.

[5]  J. Calafat,et al.  Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. , 2001, Blood.

[6]  G. Hodge,et al.  Synthesis and Surface Expression of CD14 by Human Endothelial Cells , 2001, Infection and Immunity.

[7]  H. Lilja,et al.  The Human Cationic Antimicrobial Protein (hCAP-18) Is Expressed in the Epithelium of Human Epididymis, Is Present in Seminal Plasma at High Concentrations, and Is Attached to Spermatozoa , 2000, Infection and Immunity.

[8]  E. Greenberg,et al.  Bactericidal Activity of Mammalian Cathelicidin-Derived Peptides , 2000, Infection and Immunity.

[9]  James M. Wilson,et al.  Augmentation of Innate Host Defense by Expression of a Cathelicidin Antimicrobial Peptide , 1999, Infection and Immunity.

[10]  Y. Shai,et al.  Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. , 1999, The Biochemical journal.

[11]  M. Kelm.  Nitric oxide metabolism and breakdown. , 1999, Biochimica et biophysica acta.

[12]  M. Ståhle-Bäckdahl,et al.  The Human Cationic Antimicrobial Protein (hCAP18), a Peptide Antibiotic, Is Widely Expressed in Human Squamous Epithelia and Colocalizes with Interleukin-6 , 1999, Infection and Immunity.

[13]  K. A. Kirkebøen,et al.  The role of nitric oxide in sepsis – an overview , 1999, Acta anaesthesiologica Scandinavica.

[14]  R. Gennaro,et al.  Cytotoxicity and apoptosis mediated by two peptides of innate immunity. , 1998, Cellular immunology.

[15]  Alan J. Waring,et al.  Activities of LL-37, a Cathelin-Associated Antimicrobial Peptide of Human Neutrophils , 1998, Antimicrobial Agents and Chemotherapy.

[16]  T. Kirikae,et al.  Protective Effects of a Human 18-Kilodalton Cationic Antimicrobial Protein (CAP18)-Derived Peptide against Murine Endotoxemia , 1998, Infection and Immunity.

[17]  K. Berndt,et al.  Conformation-dependent Antibacterial Activity of the Naturally Occurring Human Peptide LL-37* , 1998, The Journal of Biological Chemistry.

[18]  J. Catravas,et al.  Cytoskeleton‐dependent activation of the inducible nitric oxide synthase in cultured aortic smooth muscle cells , 1996, British journal of pharmacology.

[19]  J. Odeberg,et al.  The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. , 1996, European journal of biochemistry.

[20]  A. Johnsen,et al.  hCAP‐18, a cathelin/pro‐bactenecin‐like protein of human neutrophil specific granules , 1995, FEBS letters.

[21]  J. Larrick,et al.  Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein , 1995, Infection and immunity.

[22]  M. Ernst,et al.  Endotoxin activates human vascular smooth muscle cells despite lack of expression of CD14 mRNA or endogenous membrane CD14 , 1995, Infection and immunity.

[23]  I. Adcock,et al.  Lipopolysaccharide treatment in vivo induces widespread tissue expression of inducible nitric oxide synthase mRNA. , 1993, Biochemical and biophysical research communications.

[24]  J. Parrillo.  Pathogenetic mechanisms of septic shock. , 1993, The New England journal of medicine.

[25]  J. Parratt,et al.  Incubation with endotoxin activates the L-arginine pathway in vascular tissue. , 1990, Biochemical and biophysical research communications.

[26]  R. Cohen,et al.  Endotoxin inhibits contraction of vascular smooth muscle in vitro. , 1990, The American journal of physiology.

[27]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[28]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[29]  M. Bennett,et al.  An Introduction to Vascular Biology: The regulation of vascular smooth muscle cell apoptosis , 2002 .

[30]  E. Fleck,et al.  TNFalpha inhibits insulin's antiapoptotic signaling in vascular smooth muscle cells. , 2001, Biochemical and biophysical research communications.

[31]  R. Gennaro,et al.  Structural features and biological activities of the cathelicidin-derived antimicrobial peptides. , 2000, Biopolymers.

[32]  Y. Hirata,et al.  Phenotypic change of endothelin receptor subtype in cultured rat vascular smooth muscle cells. , 1994, Endocrinology.

[33]  R. Cohen,et al.  Interleukin 1 inhibits contraction of vascular smooth muscle. , 1989, The Journal of clinical investigation.